We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
28
3 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
1986
Completed
17
60.7%
Not yet recruiting
3
10.7%
Recruiting
8
28.6%
No approval data available
- A systematic review and meta-analysis of 13 studies found hydroxychloroquine significantly reduces proteinuria in 1010 patients with primary glomerular diseases, regardless of disease type or treatment duration. - The analysis revealed hydroxychloroquine improved estimated glomerular filtration rate specifically in patients with IgA nephropathy, though overall eGFR improvement was limited across all disease types. - In lupus nephritis patients, hydroxychloroquine use was associated with a 77% reduced risk of significant kidney function decline and decreased annual eGFR slope decline by 5.12 ml/min/1.73 m² in the first five years. - Gastrointestinal and mucocutaneous effects were the most common adverse events, accounting for approximately 58% of the 69 reported side effects across studies.